Table 1.
Patient characteristics categorized by post-remission therapy.
| Variables | Consolidation Chemotherapy (N=94) | Allo-HSCT (CR1) (N=54) | P-value |
|---|---|---|---|
| Sex, N (%) | |||
| Male | 55 (58.5) | 38 (70.4) | 0.151 |
| Age, y | |||
| Median (range) | 41 (17–74) | 33 (15–59) | <0.001 |
| WBC, ×109/L | |||
| Median (range) | 17.27 (1.15–315.62) | 18.30 (3.52–266.00) | 0.164 |
| Hemoglobin, g/L | |||
| Median (range) | 102 (47–157) | 100 (58–157) | 0.707 |
| Platelets, ×109/L | |||
| Median (range) | 27 (5–184) | 35 (2–172) | 0.363 |
| FAB type, N (%) | |||
| M2 | 88 (93.6) | 48 (88.9) | 0.483 |
| CR after first induction, N (%) | |||
| Yes | 87 (92.6) | 43 (79.6) | 0.021 |
| MRDint positivity, N/N (%) | |||
| Yes | 48/88 (54.5) | 35/51 (68.6) | 0.103 |
Allo-HSCT, allogenic hematopoietic stem cell transplantation; CR, complete remission; WBC, white blood cell; FAB, French–American–British; MRDint, minimal residual disease after induction.